TrialThe American journal of tropical medicine and hygiene2011

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Sócrates Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.